liposomal daunorubicin

Phase 3Small molecule

liposomal daunorubicin is one of 5 small molecule programs targeting Acute Myeloid Leukaemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myeloid LeukaemiaActive, not recruiting

Acute Myeloid LeukaemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Acute Myeloid Leukaemia

#DrugCompanyPhaseTrials

Cytosar

Teva

Phase 3

3 2

Fludara

Sanofi

Phase 3

1 3

Mylotarg

WWyeth-Lederle Vaccines

Phase 3

1 4

Busulfex

Akero Therapeutics

Phase 3

1 5

liposomal daunorubicin

Sanofi

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2032

Phase 3Active, not recruiting

Acute Myeloid Leukaemia

NCT02724163

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents

Unknown status·UUniversity Hospital Muenster·Phase 2/3·NCT00111345·550 enrolled

Acute Lymphoblastic Leukemia1 trial

Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Terminated· Sanofi logo

Sanofi·Phase 2·NCT03860844·67 enrolled

Acute Myeloid Leukaemia1 trial

International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy

Active, not recruiting·UUniversity of Birmingham·Phase 3·NCT02724163·700 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for liposomal daunorubicin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — liposomal daunorubicin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for liposomal daunorubicin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sanofi

liposomal daunorubicin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2032

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

Acute Lymphoblastic Leukemia1 trial

Acute Myeloid Leukaemia1 trial

References

Drug Info

Quick Facts

Related News